Drug SafetyConfirmed
The Compounded GLP-1 Boom Is Becoming a Patient-Safety and Trust Crisis
The weight-loss drug boom created a shadow market of compounded GLP-1s, fake labels, telehealth claims, dosing confusion, and patients who may not know what they are actually getting.
Why now
Regulatory warnings and investigations are converging on the same problem: patients cannot always tell what product they are receiving.
- Overclaim risk
- medium-high
- Primary source
- Investigation
- Published
- Jun 24, 2026
Read brief ->